The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
Anemia is common in Congestive Heart Failure (CHF) and is associated with an increased mortality, morbidity and progressive renal failure. The most common causes of the anemia in CHF are (1) the associated Chronic Kidney Disease (CKD), which causes depression of erythropoietin (EPO) production in the kidney, and (2) excessive cytokine production in CHF, which can cause both depression of erythropoietin production in the kidney and depression of erythropoietin response in the bone marrow. The cytokines can also induce iron deficiency by increasing hepcidin production from the liver, which both reduces gastrointestinal iron absorption and reduces iron release from iron stores located in the macrophages and hepatocytes. It appears that iron deficiency is very common in CHF and is rarely recognized or treated. The iron deficiency can cause a thrombocytosis that might contribute to cardiovascular complications in both CHF and CKD and is reversible with iron treatment. Thus, attempts to control this anemia in CHF will have to take into consideration both the use of both Erythropoiesis Stimulating Agents (ESA) such as EPO and oral and, probably more importantly, intravenous (IV) iron. Many studies of anemia in CHF with ESA and oral or IV iron and even with IV iron without ESA have shown a positive effect on hospitalization, New York Heart Association functional class, cardiac and renal function, quality of life, exercise capacity and reduced Beta Natriuretic Peptide and have not demonstrated an increase in cardiovascular damage related to the therapy. However, adequately powered long-term placebo-controlled studies of ESA and of IV iron in CHF are still needed and are currently being carried out.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, AI shares features with the renal anemia observed in patients with chronic kidney disease (CKD), the anemia in patients with chronic obstructive pulmonary disease (COPD), the anemia in patients with CHF without or with cardio-renal syndrome, and the anemia of the elderly [23, 27, 28].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [23]
In the citing paper
“Likewise, parenteral iron substitution has been found to improve the clinical course of CHF in patients with coexisting ID [22–24].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [23]
Citations
Cites
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908355 · Cited by 2,083 · cited 2×
“This suggestion gains added impetus as a result of a recent study using IV ferric carboxymaltose, the FAIR-HF study [38], a large randomized placebo-”
Anemia and Mortality in Heart Failure Patients
Groenveld, H. F., Januzzi, J. L., Damman, K., van Wijngaarden, J., Hillege, H. L., van Veldhuisen, D. J., & van der Meer, P. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.061 · Cited by 764
Iron deficiency: an ominous sign in patients with systolic chronic heart failure
Jankowska, E. A., Rozentryt, P., Witkowska, A., Nowak, J., Hartmann, O., Ponikowska, B., Borodulin-Nadzieja, L., Banasiak, W., Polonski, L., Filippatos, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq158 · Cited by 652 · cited 4×
“Indeed, iron deficiency has been found to be an independent risk factor for mortality or heart transplantation in CHF [12].”
InfluentialPhrommintikul, A., Haas, S. J., Elsik, M., & Krum, H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60194-9 · Cited by 638 · cited 1×
“On the other hand, there is concern about increased cardiovascular complications due to ESA in its use in the anemia of CKD [24] and cancer [25].”
Okonko, D. O., Grzeslo, A., Witkowski, T., Mandal, A. K. J., Slater, R. M., Roughton, M., Foldes, G., Thum, T., Majda, J., Banasiak, W., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.036 · Cited by 569 · cited 1×
“exercise and patient global assessment [37].”
New Avenues of Exploration for Erythropoietin
Maiese, K. (2005) · JAMA · doi:10.1001/jama.293.1.90 · Cited by 528 · cited 1×
“These may explain its direct protective effects in experimental animals exposed to various hypoxic and toxic states [32, 33].”
Toblli, J. E., Lombraña, A., Duarte, P., & Di Gennaro, F. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.029 · Cited by 415
Etiology of Anemia in Patients With Advanced Heart Failure
Nanas, J. N., Matsouka, C., Karageorgopoulos, D., Leonti, A., Tsolakis, E., Drakos, S. G., Tsagalou, E. P., Maroulidis, G. D., Alexopoulos, G. P., Kanakakis, J. E., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.034 · Cited by 403 · cited 1×
“In addition, bone marrow studies have confirmed the fact that many of these anemic CHF patients have no iron in their bone marrow, a powerful confirmation of the presence of iron deficiency [13].”
Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Tonelli, M., Garg, A. X., Pellegrini, F., Ravani, P., Jardine, M., Perkovic, V., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-1-201007060-00252 · Cited by 363
The non‐haematopoietic biological effects of erythropoietin
Arcasoy, M. O. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07014.x · Cited by 347 · cited 1×
“These may explain its direct protective effects in experimental animals exposed to various hypoxic and toxic states [32, 33].”
Iron metabolism in the anemia of chronic disease
Weiss, G. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.08.006 · Cited by 322
Anemia and Chronic Heart Failure
Anand, I. S. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.044 · Cited by 314
Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart Failure
Bolger, A. P., Bartlett, F. R., Penston, H. S., O’Leary, J., Pollock, N., Kaprielian, R., & Chapman, C. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.015 · Cited by 292
Opasich, C., Cazzola, M., Scelsi, L., De Feo, S., Bosimini, E., Lagioia, R., Febo, O., Ferrari, R., Fucili, A., Moratti, R., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi388 · Cited by 287 · cited 3×
“The concept that iron deficiency itself, even without anemia, is common in CHF [9, 12, 38], worsens as the Hb falls [12, 39], is an independent risk factor for mortality [12] and may play a role in the causation or worsening of CHF is really extremely interesting since iron deficiency can be easily detected by blood t…”
Ghali, J. K., Anand, I. S., Abraham, W. T., Fonarow, G. C., Greenberg, B., Krum, H., Massie, B. M., Wasserman, S. M., Trotman, M.-L., Sun, Y., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.698514 · Cited by 270
Iron regulation and erythropoiesis
Nemeth, E. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282f73335 · Cited by 181
Myocardial and Systemic Iron Depletion in Heart Failure
Maeder, M. T., Khammy, O., dos Remedios, C., & Kaye, D. M. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.01.059 · Cited by 178 · cited 1×
“In a preliminary human study of cardiac tissue in CHF, a low iron content was found by atomic adsorption spectroscopy [ 14 ].”
Dong, F., Zhang, X., Culver, B., Chew, H. G., Kelley, R. O., & Ren, J. (2005) · Clinical Science · doi:10.1042/cs20040278 · Cited by 171 · cited 1×
“It is known from animal studies that iron deficiency greatly disturbs cellular function, especially mitochondrial production of energy [40, 41].”
Adaptive response of the heart to long-term anemia induced by iron deficiency
Naito, Y., Tsujino, T., Matsumoto, M., Sakoda, T., Ohyanagi, M., & Masuyama, T. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00463.2008 · Cited by 171 · cited 1×
“It is known from animal studies that iron deficiency greatly disturbs cellular function, especially mitochondrial production of energy [40, 41].”
Tang, W. H. W., Tong, W., Jain, A., Francis, G. S., Harris, C. M., & Young, J. B. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.094 · Cited by 164 · cited 1×
“spontaneous fall in Hb over time and improves if there is a spontaneous rise in Hb over time [4, 7].”
The Role of Medical Liability Reform in Federal Health Care Reform
Mello, M. M., & Brennan, T. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0903765 · Cited by 163
Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., Cella, D. F., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., et al. (2008) · Blood · doi:10.1182/blood-2007-08-109488 · Cited by 151 · cited 1×
“On the other hand, there is concern about increased cardiovascular complications due to ESA in its use in the anemia of CKD [24] and cancer [25].”
Chronic Heart Failure: Current Evidence, Challenges to Therapy, and Future Directions
Morrissey, R. P., Czer, L. S. C., & Shah, P. K. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11592090-000000000-00000 · Cited by 137
Usmanov, R. I., Zueva, E. B., Silverberg, D. S., & Shaked, M. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.2.236 · Cited by 130
Self-citationErythropoietin treatment in patients with chronic heart failure: a meta-analysis
van der Meer, P., Groenveld, H. F., Januzzi, J. L., & van Veldhuisen, D. J. (2009) · Heart · doi:10.1136/hrt.2008.161091 · Cited by 130
McMurray, J. J. V., Anand, I. S., Diaz, R., Maggioni, A. P., O’Connor, C., Pfeffer, M. A., Polu, K. R., Solomon, S. D., Sun, Y., Swedberg, K., et al. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp098 · Cited by 119 · cited 1×
“efficacy of ESA in this condition and the results of larger multicentered double-blind placebo-controlled studies of ESA in CHF such as the RED-HF study of darbepoetin are eagerly awaited [29].”
Boerrigter, G., Costello‐Boerrigter, L. C., Abraham, W. T., Sutton, M. G. S. J., Heublein, D. M., Kruger, K. M., Hill, M. R. S., McCullough, P. A., & Burnett, J. C. J. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.03.009 · Cited by 105 · cited 1×
“That CHF is a major contributor to CKD has been emphasized by recent studies of resynchronization treatment in CHF patients with LBBB and asynchronous cardiac contraction [ 8 ].”
Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Ngo, K., Kotecha, D., Walters, J. A., Manzano, L., Palazzuoli, A., van Veldhuisen, D. J., & Flather, M. D. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007613.pub2 · Cited by 80
Szczech, L. A., Barnhart, H. X., Sapp, S., Felker, G. M., Hernandez, A., Reddan, D., Califf, R. M., Inrig, J. K., Patel, U. D., & Singh, A. K. (2010) · Kidney International · doi:10.1038/ki.2009.415 · Cited by 73
Abramov, D., Cohen, R. S., Katz, S. D., Mancini, D., & Maurer, M. S. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.05.058 · Cited by 69 · cited 1×
“The anemia in CHF is thus usually associated with a combination of both increased plasma volume and reduced red cell mass [16].”
Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome
Besarab, A., Hörl, W. H., & Silverberg, D. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-s1-22 · Cited by 69 · cited 1×
“Iron deficiency of any cause can cause increased production and activation of platelets and may thus cause a hypercoagulable state [15].”
Self-citationInsulin Sensitivity in African‐American and White Women: Association With Inflammation
Hyatt, T. C., Phadke, R. P., Hunter, G. R., Bush, N. C., Muñoz, A. J., & Gower, B. A. (2009) · Obesity · doi:10.1038/oby.2008.549 · Cited by 67
Iron Regulatory Hormone Hepcidin Decreases in Chronic Heart Failure Patients With Anemia
Matsumoto, M., Tsujino, T., Lee-Kawabata, M., Naito, Y., Akahori, H., Sakoda, T., Ohyanagi, M., Tomosugi, N., & Masuyama, T. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0663 · Cited by 59 · cited 1×
“The concept that iron deficiency itself, even without anemia, is common in CHF [9, 12, 38], worsens as the Hb falls [12, 39], is an independent risk factor for mortality [12] and may play a role in the causation or worsening of CHF is really extremely interesting since iron deficiency can be easily detected by blood t…”
Ghali, J. K. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328324ecec · Cited by 59
The Impact of Anemia on the Prognosis of Chronic Heart Failure: A Meta‐Analysis and Systemic Review
He, S., & Wang, L. (2009) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2008.00030.x · Cited by 57
The Role of Correction of Anaemia in Patients with Congestive Heart Failure: A Short Review
Silverberg, D. S., Wexlerb, D., Iaina, A., & Schwartz, D. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.06.015 · Cited by 47
Self-citationDesai, A. S., Lewis, E. F., Solomon, S. D., McMurray, J. J. V., & Pfeffer, M. A. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq094 · Cited by 43 · cited 1×
“The pooled risk ratio for ESA treatment relative to placebo was not significant for overall mortality (1.03) or for worsening CHF (1.10) [ 23 ].”
InfluentialSilverberg, D. S., Wexler, D., Palazzuoli, A., Iaina, A., & Schwartz, D. (2009) · Acta Haematologica · doi:10.1159/000243795 · Cited by 37 · cited 2×
“ment of all three could prevent the progression of all three conditions [1, 3].”
Self-citationKlapholz, M., Abraham, W. T., Ghali, J. K., Ponikowski, P. P., Anker, S. D., Knüsel, B., Sun, Y. P., Wasserman, S. M., & van Veldhuisen, D. J. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp130 · Cited by 33 · cited 1×
“In a pooled analysis of 3 placebocontrolled darbepoetin studies in CHF that had a target Hb of 14 ± 1 g/dl and included a total of 516 patients, there were no differences in the rate of adverse effects or death compared to placebo [ 22 ].”
Erythropoiesis Stimulating Agents in Heart Failure Patients with Anemia: A Meta-Analysis
Tehrani, F., Dhesi, P., Daneshvar, D. A., Phan, A., Rafique, A. M., Siegel, R. J., & Cercek, B. (2009) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-009-6203-6 · Cited by 16
Berns, J. S. (2010) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32833c3cc7 · Cited by 13 · cited 1×
“Some would argue that a target Hb of 10–12 g/dl is currently sufficient for CKD [30, 31].”
Singh, A. K. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010020178 · Cited by 13 · cited 1×
“Some would argue that a target Hb of 10–12 g/dl is currently sufficient for CKD [30, 31].”
Cited by
Ronco, C., Cicoira, M., & McCullough, P. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.077 · Cited by 422
“Anemia is common in HF and is associated with increased mortality, morbidity, and worsening renal function (31).”
The role of the kidney in heart failure
Metra, M., Cotter, G., Gheorghiade, M., Dei Cas, L., & Voors, A. A. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs205 · Cited by 258
“The inflammatory activation associated with HF inhibits renal erythropoietin production, causing resistance to erythropoietin and iron deficiency, through reduced absorption and decreased release from stores in macrophages and hepatocytes.(46)”
BackgroundPrevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure
Cleland, J. G. F., Zhang, J., Pellicori, P., Dicken, B., Dierckx, R., Shoaib, A., Wong, K., Rigby, A., Goode, K., & Clark, A. L. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1161 · Cited by 175
Filippatos, G., Farmakis, D., Colet, J. C., Dickstein, K., Lüscher, T. F., Willenheimer, R., Parissis, J., Gaudesius, G., Mori, C., von Eisenhart Rothe, B., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft099 · Cited by 157
Nairz, M., Theurl, I., Wolf, D., & Weiss, G. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-016-0505-7 · Cited by 152
Metadata
- Authors
- Silverberg, D. S.
- Affiliations
- Tel Aviv Sourasky Medical Center (IL)
- Corresponding author
- Silverberg, Donald S.
- Venue
- Heart Failure Reviews
- Published
- 2010-09-24
- Volume
- 16
- Issue
- 6
- Pages
- 609-614
- ISSN
- 1382-4147 (ISSN-L)
- 1573-7322
- OpenAlex
- W2091404630
- Cited by
- 48
- References
- 44
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 2 · 2020: 1 · 2019: 5 · 2018: 4 · 2017: 3 · 2016: 4 · 2015: 3 · 2014: 6 · 2013: 4 · 2012: 8
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Heart Failure Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- cardiorenal anemia syndrome, congestive heart failure, anemia, erythropoiesis-stimulating agents, intravenous iron, erythropoietin, chronic kidney disease, iron deficiency, hepcidin, cytokines, thrombocytosis, renal function, cardiovascular outcomes
- MeSH terms
- Iron Deficiencies, Anemia, Bone Marrow, Cardiovascular System, Clinical Trials as Topic, Erythropoietin, Heart Failure, Hematinics, Humans, Infusions, Intravenous, Iron, Kidney, Syndrome, Trace Elements, Outcome Assessment, Health Care, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.